Biotech Stocks on Investors' Radar -- Merrimack Pharma, Amicus Therapeutics, CEL-SCI, and Cempra

Thursday, April 6, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 6, 2017 /PRNewswire/ -- today draws investors' attention to Merrimack Pharmaceuticals

Inc. (NASDAQ: MACK), Amicus Therapeutics Inc. (NASDAQ: FOLD), CEL-SCI Corp. (NYSE MKT: CVM), and Cempra Inc. (NASDAQ: CEMP). According to an article on Seeking Alpha, despite a solid first quarter, the Biotech industry spent most of March consolidating
the ~10% rise it saw in February. The iShares Nasdaq Biotechnology index spent almost the entire month of March locked in a tight range of ~290 to ~300, and continues to trade just under long-term resistance levels, which have in place since very late in 2015. Learn more about these stocks by downloading their comprehensive and free reports at:

Merrimack Pharma  

On Wednesday, shares in Cambridge, Massachusetts headquartered Merrimack Pharmaceuticals Inc. saw a drop of 3.40%, ending the day at $3.13. The stock recorded a trading volume of 2.76 million shares. The Company's shares have advanced 2.29% in the last one month. The stock is trading above its 50-day moving average by 0.19%. Moreover, shares of Merrimack Pharma, which engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the US, have a Relative Strength Index (RSI) of 50.59.

On April 03rd, 2017, Merrimack Pharma announced that it has commenced operating as a new, refocused research and clinical development company in connection with the completion of its previously announced transaction with Ipsen S.A. valued at up to $1.025 billion. Merrimack received $575 million in cash upon closing, and is eligible to receive up to $450 million in additional regulatory approval-based milestone payments. MACK complete research report is just a click away and free at:

Amicus Therapeutics  

Shares in Cranbury, New Jersey headquartered Amicus Therapeutics Inc. ended the day 3.60% lower at $6.97, with a total trading volume of 3.21 million shares. In the previous three months and since the start of this year, the stock has gained 23.80% and 40.24%, respectively. The Company's shares are trading above their 50-day and 200-day moving averages by 5.90% and 5.22%, respectively. Furthermore, shares of Amicus Therapeutics, which engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases, have an RSI of 48.35.

On April 03rd, 2017, Amicus Therapeutics announced that the Company has completed enrollment in its ongoing Phase-3 clinical study (ESSENCE) of the novel topical medicine SD-101 for patients with all three major types of epidermolysis bullosa: Simplex, Recessive Dystrophic, and Junctional non-Herlitz. With the achievement of full enrollment, top-line data from this study are expected in Q3 2017. The complimentary report on FOLD can be downloaded at:


At the close of trading on Wednesday, shares in Vienna, Virginia headquartered CEL-SCI Corp. finished 0.13% higher at $0.08, with a total trading volume of 1.55 million shares. The stock has advanced 0.13% over the previous three months and 14.43% on an YTD basis. The Company's shares are trading below their 50-day moving average by 22.98%. Additionally, shares of CEL-SCI, which engages in the research and development of drugs and vaccines, have an RSI of 37.80. Sign up for your complimentary research report on CVM at:


Chapel Hill, North Carolina headquartered Cempra Inc.'s shares recorded a trading volume of 1.26 million shares at the end of yesterday's session. The stock closed the day flat at $3.80. The Company's shares have advanced 8.57% in the past month, 16.92% in the last three months, and 35.71% on an YTD basis. The stock is trading above its 50-day moving average by 7.56%. Additionally, shares of Cempra, which focuses on developing anti-infectives for the acute care and community settings to meet critical medical needs in the treatment of infectious diseases in North America, have an RSI of 50.16.

On March 28th, 2017, Cempra announced that it has withdrawn its marketing authorization application (MAA) seeking European Medicines Agency (EMA) approval of oral capsule and intravenous formulations of solithromycin for the treatment of community-acquired pneumonia in adults. By withdrawing the MAA, Cempra will conserve considerable financial resources, and be able to align its strategy to provide additional data to both the EMA and US FDA to support potential approval.

On March 29th, 2017, research firm Gabelli & Co downgraded the Company's stock rating from 'Hold' to 'Sell'. Get free access to your research report on CEMP at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store